Sirolimus is effective in immune-mediated hematopoiesis, such as autoimmune lymphoproliferative syndrome and Evans syndrome, but is not effective in thrombocytopenia caused by other diseases such as leukemia.
1. Sirolimus belongs to a kind of immune agent, which can be used to treat thrombocytopenia, and good results can be obtained by combining with other drugs (it is recommended to combine with cyclosporine and corticosteroids).
It is effective in autoimmune lymphoproliferative syndrome, Evans syndrome, primary immune thrombocytopenia, and many other immune-mediated blood cell reductions.
2. Ineffective in thrombocytopenia caused by other diseases such as leukemia, severe infections, and liver disease.
Sirolimus belongs to prescription drugs, adverse reactions include thrombocytopenia, hyperlipidemia, hypertension, anemia, arthralgia, hypokalemia, diarrhea, etc. It is forbidden for patients with severe hepatic and renal impairment and allergy, patients should not use the drug privately, and need to use the drug regularly under the guidance of the doctor, so as not to cause adverse reactions. Patients should review regularly during the medication period to avoid adverse effects on the body.